A regulatory circuit that involves HR23B and HDAC6 governs the biological response to HDAC inhibitors.
Histone deacetylase (HDAC) is an emergent anticancer target, and HR23B is a biomarker for response to HDAC inhibitors. We show here that HR23B has impacts on two documented effects of HDAC inhibitors; HDAC inhibitors cause apoptosis in cells expressing high levels of HR23B, whereas in cells with low...
Hoofdauteurs: | New, M, Olzscha, H, Liu, G, Khan, O, Stimson, L, McGouran, J, Kerr, D, Coutts, A, Kessler, B, Middleton, M, La Thangue, N |
---|---|
Formaat: | Journal article |
Taal: | English |
Gepubliceerd in: |
2013
|
Gelijkaardige items
-
A regulatory circuit that involves HR23B and HDAC6 governs the biological response to HDAC inhibitors
door: New, M, et al.
Gepubliceerd in: (2013) -
HR23B is a biomarker for tumor sensitivity to HDAC inhibitor-based therapy.
door: Khan, O, et al.
Gepubliceerd in: (2010) -
Role of HR23B, HDAC6 and Myd88 and their interplay in response to HDAC inhibitor treatment
door: New, M
Gepubliceerd in: (2014) -
HR23B, a biomarker for HDAC inhibitors
door: Khan, OA
Gepubliceerd in: (2013) -
Biomarkers for predicting clinical responses to HDAC inhibitors.
door: Stimson, L, et al.
Gepubliceerd in: (2009)